KNSA vs REGN: Which Stock is Better?
Side-by-side comparison of Kiniksa Pharmaceuticals International Plc and Regeneron Pharmaceuticals Inc in 2026
KNSA
Kiniksa Pharmaceuticals International Plc
$45.89
REGN
Regeneron Pharmaceuticals Inc
$753.93
Key Metrics Comparison
| Metric | KNSA | REGN | Winner |
|---|---|---|---|
| Market Cap | $3.59B | $79.87B | REGN |
| P/E Ratio | 62.56 | 18.21 | REGN |
| EPS (TTM) | $0.75 | $41.48 | REGN |
| Revenue Growth | 0.7% | 0.0% | KNSA |
| Gross Margin | 54.7% | 44.6% | KNSA |
Analyze KNSA
Full quant analysis
Analyze REGN
Full quant analysis
Analyze Each Stock
Frequently Asked Questions
Is KNSA or REGN a better investment?
Comparing KNSA and REGN: Kiniksa Pharmaceuticals International Plc has a market cap of $3.59B while Regeneron Pharmaceuticals Inc has $79.87B. Both companies have their strengths - use our detailed metrics comparison to make an informed decision.
What is the difference between KNSA and REGN?
KNSA (Kiniksa Pharmaceuticals International Plc) and REGN (Regeneron Pharmaceuticals Inc) differ in valuation, growth rates, and profitability metrics. Our comparison shows which company leads in each category.
Which stock has better value: KNSA or REGN?
Based on P/E ratios, REGN trades at a lower multiple (18.2x vs 62.6x).
Which is growing faster: KNSA or REGN?
KNSA has higher revenue growth at 0.7% vs 0.0% for REGN.
Which company is more profitable: KNSA or REGN?
Kiniksa Pharmaceuticals International Plc (KNSA) has higher gross margins at 54.7% compared to 44.6% for REGN.
Which is the larger company: KNSA or REGN?
Regeneron Pharmaceuticals Inc (REGN) is larger with a market cap of $79.87B compared to $3.59B for KNSA.
Should I buy KNSA or REGN in 2026?
Both KNSA and REGN have investment merit. KNSA trades at $45.89 while REGN trades at $753.93. Consider your investment goals, risk tolerance, and portfolio diversification before deciding. Our AI analysis tools can provide personalized insights.
What are the key differences between KNSA and REGN stock?
Key differences: Market Cap ($3.59B vs $79.87B), P/E Ratio (62.6x vs 18.2x), Revenue Growth (0.7% vs 0.0%), Gross Margin (54.7% vs 44.6%).